PCGONDO Stock Latest News
Private CompaniesCommunity Engagement Underscores GondolaBio’s Focus on Rare Disease Segment5d agoGONDO
Private CompaniesGondolaBio Highlights Patient-Centric Focus in Charcot-Marie-Tooth Summit Participation1w agoGONDO
Private CompaniesGondolaBio Highlights Engagement With Nano-Rare Disease Community1w agoGONDO
Private CompaniesGondolaBio Deepens Patient-Centric Engagement in Porphyria Community1w agoGONDO
Private CompaniesLeadership Recognition Underscores GondolaBio’s Pipeline Execution Focus2w agoGONDO
Private CompaniesGondolaBio Highlights Rare-Disease Focus With EPP And XLP Program3w agoGONDOPrivate CompaniesGondolaBio Highlights Engagement at Rare Disease Drug Development Symposium1M agoGONDO
Private CompaniesGondolaBio Highlights Focus on Charcot-Marie-Tooth Awareness and Research1M agoGONDO- Private CompaniesGondolaBio Engages Rare Disease Community at 2026 Dup15q & Angelman Conference2M agoGONDO
Private CompaniesGondolaBio Highlights Patient-Centric Focus in Rare Disease Efforts2M agoGONDO
Private CompaniesGondolaBio Highlights Engagement With Tuberous Sclerosis Community2M agoGONDO
Private CompaniesGondolaBio Deepens Rare Disease Community Engagement to Inform Future Research2M agoGONDOPrivate CompaniesPatient-Centric Engagement Highlights GondolaBio’s Focus on Rare Disease Communities2M agoGONDO
Private CompaniesGondolaBio Highlights Patient-Centric Engagement in Rare Disease Research3M agoGONDO
Private CompaniesGondolaBio Highlights Focus on EPP Patient Needs and Rare Disease Research3M agoGONDO
Private CompaniesGondolaBio Emphasizes Patient-Centric Strategy in Rare Genetic Diseases3M agoGONDO
Private CompaniesGondolaBio Highlights Positive Phase 2a Data for Rare-Disease Candidate PORT-774M agoGONDOPrivate CompaniesGondolaBio Bolsters PORT-77 Visibility and Rare-Disease Community Ties in Busy Week4M agoGONDO
Private CompaniesClinician Webinars Highlight Phase 2a Data and Plans for PORT-77 in Porphyria4M agoGONDO